New  	New  	 JJ	B-NP
horizons  	horizons  	 NNS	I-NP
in  	in  	 IN	O
the  	the  	 DT	O
pharmacologic  	pharmacologic  	 JJ	B-NP
approach  	approach  	 NN	I-NP
to  	to  	 TO	O
hyponatremia 	hyponatremia 	 VB	O
:  	:  	 :	O
the  	the  	 DT	O
V2  	V2  	 JJ	B-NP
receptor  	receptor  	 NN	I-NP
antagonists  	antagonists  	 VBD	I-NP
This  	This  	 DT	O
article  	article  	 NN	O
provides  	provides  	 VBZ	O
an  	an  	 DT	O
overview  	overview  	 NN	B-NP
of  	of  	 IN	O
the  	the  	 DT	O
developing  	developing  	 VBG	O
niche  	niche  	 NN	O
for  	for  	 IN	O
vasopressin  	vasopressin  	 CD	B-NP
2  	2  	 CD	O
receptor  	receptor  	 NN	B-NP
antagonists  	antagonists  	 NNS	I-NP
( 	( 	 -LRB-	O
vaptans 	vaptans 	 LS	B-NP
)  	)  	 -RRB-	O
in  	in  	 IN	O
the  	the  	 DT	O
management  	management  	 NN	O
of  	of  	 IN	O
hyponatremia  	hyponatremia  	 NN	B-NP
in  	in  	 IN	O
clinical  	clinical  	 JJ	B-NP
practice 	practice 	 NN	I-NP
.  	.  	 .	O
Specific  	Specific  	 JJ	B-NP
areas  	areas  	 NNS	I-NP
of  	of  	 IN	O
focus  	focus  	 NN	O
include  	include  	 VBP	O
the  	the  	 DT	O
physiological  	physiological  	 NN	O
and  	and  	 CC	O
clinical  	clinical  	 JJ	B-NP
rationale  	rationale  	 NN	I-NP
for  	for  	 IN	O
use  	use  	 NN	O
of  	of  	 IN	O
this  	this  	 DT	O
class  	class  	 NN	O
of  	of  	 IN	O
medications  	medications  	 NNS	O
( 	( 	 -LRB-	O
including  	including  	 VBG	B-NP
advantages  	advantages  	 NNS	I-NP
over  	over  	 IN	O
older  	older  	 JJR	O
and  	and  	 CC	O
less  	less  	 RBR	O
specific  	specific  	 JJ	O
therapeutic  	therapeutic  	 JJ	B-NP
modalities 	modalities 	 NN	I-NP
) 	) 	 -RRB-	O
,  	,  	 ,	O
the  	the  	 DT	O
practical  	practical  	 JJ	B-NP
limitations  	limitations  	 NNS	I-NP
to  	to  	 TO	O
the  	the  	 DT	O
use  	use  	 NN	O
of  	of  	 IN	O
these  	these  	 DT	O
new  	new  	 JJ	O
drugs  	drugs  	 NNS	O
( 	( 	 -LRB-	O
including  	including  	 VBG	B-NP
issues  	issues  	 NNS	I-NP
of  	of  	 IN	I-NP
tolerability 	tolerability 	 NN	I-NP
,  	,  	 ,	O
toxicity 	toxicity 	 NN	O
,  	,  	 ,	O
risk 	risk 	 NN	O
,  	,  	 ,	O
and  	and  	 CC	O
cost 	cost 	 NN	O
) 	) 	 -RRB-	O
,  	,  	 ,	O
and  	and  	 CC	O
the  	the  	 DT	O
unanswered  	unanswered  	 JJ	O
question  	question  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
extent  	extent  	 NN	O
to  	to  	 TO	O
which  	which  	 WDT	O
correcting  	correcting  	 VBP	B-NP
hyponatremia  	hyponatremia  	 NNS	I-NP
will  	will  	 MD	O
improve  	improve  	 VB	O
clinical  	clinical  	 JJ	B-NP
outcomes 	outcomes 	 NNS	I-NP
.  	.  	 .	O
